Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next predicted deadline: Nov 6, 2023 (Letter of inquiry)

Later predicted deadlines: Dec 6, 2023 (Full proposal), Mar 4, 2024 (Letter of inquiry), Apr 4, 2024 (Full proposal), Jul 6, 2024 (Letter of inquiry), Aug 6, 2024 (Full proposal), Nov 6, 2024 (Letter of inquiry), Dec 6, 2024 (Letter of inquiry), Mar 9, 2025 (Letter of inquiry), Apr 9, 2025 (Letter of inquiry), Jul 6, 2025 (Letter of inquiry), Aug 6, 2025 (Full proposal), Nov 5, 2025 (Letter of inquiry), Dec 5, 2025 (Full proposal)

Grant amount: Up to US $400,000

Funding uses: Research

Location of project: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico, Virgin Islands Show all

Location of residency: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico, Virgin Islands Show all

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization. 

Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) Direct costs are limited to $400,000 over a two-year period, with no more than $250,000 in direct costs in any single year. The scope of the proposed project should determine the project period. The maximum project period is two years.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.